Skip to main navigation Skip to search Skip to main content

Impact of Sex on Clinical and Angiographic Outcomes Among Patients Undergoing Revascularization With Drug-Eluting Stents

  • GG Stefanini
  • , B Kalesan
  • , T Pilgrim
  • , L Raber
  • , Yoshinobu Onuma
  • , S Silber
  • , PWJC (Patrick) Serruys
  • , B Meier
  • , P Juni
  • , S Windecker
  • External organisation

Research output: Contribution to journalArticleAcademic

68 Citations (Scopus)

Abstract

Objectives The goal of this study was to investigate sex-based differences in long-term clinical and angiographic outcomes after coronary revascularization with drug-eluting stents (DES). Background The impact of sex on clinical and angiographic outcomes following revascularization with DES is not well established. Methods Individual patient data from 3 all-comers randomized DES trials (SIRTAX, LEADERS, RESOLUTE All-Comers) were pooled. Of 5,011 patients, 4,885 (97.5%) completed 2-year follow-up (1,164 women, 3,721 men). Protocol-mandated angiographic follow-up was available for 1,561 lesions (351 among women, 1,210 among men). The primary endpoint was the composite of cardiac death and myocardial infarction (MI) at 2 years. Results At baseline, women, as compared with men, were older, more frequently had diabetes, obesity, and hypertension, less frequently had smoking habits, previous MI, and previous surgical revascularization, and had a smaller reference diameter of the target vessel as well as a lower SYNTAX score. After adjustment for baseline differences, women and men had a similar risk of cardiac death or MI (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 0.82 to 1.56, p = 0.44), cardiac death (OR: 1.0 Conclusions The unrestricted use of DES is associated with similar long-term safety and efficacy among women and men with coronary artery disease. (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization [SIRTAX]; NCT00297661, LEADERS Trial Limus Eluted From A Durable Versus ERodable Stent Coating [LEADERS]; NCT00389220, RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Interv
Original languageUndefined/Unknown
Pages (from-to)301-310
Number of pages10
JournalJACC-Cardiovascular interventions
Volume5
Issue number3
DOIs
Publication statusPublished - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research programs

  • EMC COEUR-09

Cite this